Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome

Minimal change disease (MCD) accounts for 15% of adult nephrotic syndrome (NS) cases. Adult-MCD patients may have more severe clinical features than pediatric patients. In children, Rituximab (RTX) has been used since 2006 to treat frequently relapsing NS. In adults, data about the efficacy of RTX f...

Descripción completa

Detalles Bibliográficos
Autores principales: Fenoglio, Roberta, Sciascia, Savino, Beltrame, Giulietta, Mesiano, Paola, Ferro, Michela, Quattrocchio, Giacomo, Menegatti, Elisa, Roccatello, Dario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper: Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6034752/
https://www.ncbi.nlm.nih.gov/pubmed/29989000
http://dx.doi.org/10.18632/oncotarget.25612

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6034752/
https://www.ncbi.nlm.nih.gov/pubmed/29989000
http://dx.doi.org/10.18632/oncotarget.25612

Ejemplares similares